[{"address1": "11711 North Meridian Street", "address2": "Suite 300", "city": "Carmel", "state": "IN", "zip": "46032", "country": "United States", "phone": "(317) 659-0200", "website": "https://mbxbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.", "fullTimeEmployees": 43, "companyOfficers": [{"maxAge": 1, "name": "Mr. Peter Kent Hawryluk MBA", "age": 55, "title": "CEO, President & Director", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 788300, "exercisedValue": 0, "unexercisedValue": 12366896}, {"maxAge": 1, "name": "Mr. Richard B. Bartram CPA", "age": 43, "title": "Chief Financial Officer", "yearBorn": 1981, "fiscalYear": 2024, "totalPay": 642001, "exercisedValue": 0, "unexercisedValue": 3084960}, {"maxAge": 1, "name": "Dr. Salomon  Azoulay M.D.", "age": 66, "title": "Chief Medical Officer", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 520512, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matt  Gambino", "title": "Vice President of Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michelle  Graham", "age": 57, "title": "Chief Human Resources Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael A. Dorato DABT, Ph.D.", "title": "Sr. Vice President of Discovery & Non-Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Chatan  Charan Ph.D.", "title": "Senior VP of Pharmaceutical Development & Chemistry, Manufacturing and Controls", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Hope", "title": "Senior Vice President of Regulatory & Quality", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 10.65, "open": 10.74, "dayLow": 10.39, "dayHigh": 11.17, "regularMarketPreviousClose": 10.65, "regularMarketOpen": 10.74, "regularMarketDayLow": 10.39, "regularMarketDayHigh": 11.17, "payoutRatio": 0.0, "forwardPE": -4.7896996, "volume": 162265, "regularMarketVolume": 162265, "averageVolume": 276609, "averageVolume10days": 251140, "averageDailyVolume10Day": 251140, "bid": 11.01, "ask": 11.32, "bidSize": 1, "askSize": 1, "marketCap": 373016288, "fiftyTwoWeekLow": 4.807, "fiftyTwoWeekHigh": 27.5, "fiftyDayAverage": 8.7262, "twoHundredDayAverage": 15.2168455, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 132359984, "profitMargins": 0.0, "floatShares": 13610404, "sharesOutstanding": 33424400, "sharesShort": 5382464, "sharesShortPriorMonth": 5078957, "sharesShortPreviousMonthDate": 1743379200, "dateShortInterest": 1745971200, "sharesPercentSharesOut": 0.161, "heldPercentInsiders": 0.03115, "heldPercentInstitutions": 1.0679799, "shortRatio": 14.95, "shortPercentOfFloat": 0.3238, "impliedSharesOutstanding": 33424400, "bookValue": 7.043, "priceToBook": 1.5845519, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -73465000, "trailingEps": -2.2, "forwardEps": -2.33, "enterpriseToEbitda": -1.631, "52WeekChange": -0.54968286, "SandP52WeekChange": 0.11469197, "quoteType": "EQUITY", "currentPrice": 11.16, "targetHighPrice": 44.0, "targetLowPrice": 30.0, "targetMeanPrice": 37.4, "targetMedianPrice": 38.0, "recommendationMean": 1.4, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 240786000, "totalCashPerShare": 7.204, "ebitda": -81136000, "totalDebt": 130000, "quickRatio": 23.106, "currentRatio": 23.307, "debtToEquity": 0.055, "returnOnAssets": -0.31677, "returnOnEquity": -0.48216, "freeCashflow": -42097624, "operatingCashflow": -66649000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "MBX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1747426474, "regularMarketTime": 1747425602, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1726234200000, "postMarketChangePercent": 3.0466, "postMarketPrice": 11.5, "postMarketChange": 0.34, "regularMarketChange": 0.5100002, "regularMarketDayRange": "10.39 - 11.17", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 276609, "fiftyTwoWeekLowChange": 6.3529997, "fiftyTwoWeekLowChangePercent": 1.3216141, "fiftyTwoWeekRange": "4.807 - 27.5", "fiftyTwoWeekHighChange": -16.34, "fiftyTwoWeekHighChangePercent": -0.59418184, "fiftyTwoWeekChangePercent": -54.968285, "earningsTimestamp": 1747051200, "earningsTimestampStart": 1747051200, "earningsTimestampEnd": 1747051200, "isEarningsDateEstimate": false, "shortName": "MBX Biosciences, Inc.", "longName": "MBX Biosciences, Inc.", "regularMarketChangePercent": 4.788735, "regularMarketPrice": 11.16, "marketState": "CLOSED", "epsTrailingTwelveMonths": -2.2, "epsForward": -2.33, "epsCurrentYear": -2.67222, "priceEpsCurrentYear": -4.176303, "fiftyDayAverageChange": 2.4337997, "fiftyDayAverageChangePercent": 0.27890718, "twoHundredDayAverageChange": -4.0568457, "twoHundredDayAverageChangePercent": -0.26660228, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-09-13", "averageAnalystRating": "1.4 - Strong Buy", "cryptoTradeable": false, "exchange": "NMS", "messageBoardId": "finmb_613097171", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "MBX Biosciences", "trailingPegRatio": null, "__fetch_time": "2025-05-17"}]